132 results about "Neurodevelopmental disorder" patented technology

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

The invention provides a neural developmental disorder prediction model construction method, system and device and a medium, and the method comprises the steps: obtaining the clinical information of a child patient, the clinical information comprises severity of developmental retardation / dyspepsia, complexity of syndromic neurodevelopmental disorder, autism spectrum disorder, epilepsy, attention deficit hyperactivity disorder, head circumference deformity, brain development deformity, hearing / visual function impairment and related ear-eye development deformity; applying logistic regression analysis to screen out predictive factors significantly related to the positive diagnosis rate of third-generation whole exon genome sequencing in the clinical information; constructing a neural developmental disorder prediction model based on binary logistic regression according to the prediction factor; and verifying the neurodevelopmental disorder prediction model by applying data of the internal verification group and the external verification group so as to evaluate the prediction efficiency of the neurodevelopmental disorder prediction model, so that the probability of obtaining positive diagnosis after the child patient receives trio-WES detection can be accurately evaluated, and the prediction efficiency is remarkably improved.

The present invention is directed to genetic manipulation of neural cells in the gyrencephalic fetal brain for developing treatment strategies for various neurodevelopmental disorders.

Provided are apparatuses, a non-transitory computer-readable medium or media, for predicting of neurodevelopmental disorder using a fundus image of a subject. In certain aspects, disclosed a method including the steps of: receiving the fundus image; processing the fundus image to classify one or more features contained in the fundus image using a machine learning model; and predicting, based on a classification, whether the fundus image is indicative of presence of neurodevelopmental disorder in the subject, wherein the machine learning model has been trained on stored fundus images obtained from at least two group of subjects who have previously been diagnosed as having the neurodevelopmental disorder, the machine learning model is trained by processes comprising; extracting a first embedding vector and a second embedding vector from a first fundus image and a second fundus image, respectively; and maximizing a similarity between the first embedding vector and the second embedding vector.

Embodiments of the invention provide a solution for ameliorating microbiome effects on neurodevelopment by developing a probiotic composition for consumption by a female during gestation. In certain aspects the probiotic is a multi-strain probiotic cocktail consisting of immunomodulatory taxa and administered females during pregnancy and lactation.

The invention discloses an intelligent evaluation and intervention system for child neurodevelopmental disorders, relates to the technical field of child neurodevelopmental disorder evaluation, and aims to provide comprehensive and accurate behavior, language and cognitive ability evaluation for children through advanced artificial intelligence, big data and multi-modal technologies and generate a personalized intervention scheme according to an evaluation result. The system comprises an evaluation module, an intervention module and a data analysis and feedback module, the evaluation module is combined with computer vision, voice recognition, natural language processing and eye movement tracking technologies, behavior, language and cognitive data of children are automatically collected, and a behavior score, a language score and a cognitive score are generated; the intervention module automatically adjusts the intervention intensity according to the scores; and the data analysis and feedback module analyzes the evaluation result and the intervention effect in real time, generates a personalized evaluation report and optimizes the intervention scheme. According to the invention, through an intelligent algorithm and an automatic process, the evaluation efficiency and accuracy are greatly improved.

The invention discloses a neural development disorder co-disease identification system based on a residual image neural network. Belongs to the technical field of neurodevelopment disorder co-disease recognition, and particularly relates to the technical field of co-disease recognition based on a neural network. The system comprises a data acquisition module for acquiring a resting-state fMRI image; the data preprocessing module is used for extracting standardized time sequences of 116 brain regions of the set resting state fMRI image; the multi-band division and feature extraction module is used for performing frequency band filtering on the standardized time sequence of each brain region to obtain a time sequence after each frequency band filtering; in each frequency band, constructing a binary topological matrix based on the PLV matrix and calculating a PLV feature vector based on the PLV matrix; the neurodevelopmental disorder co-disease recognition module is used for analyzing the brain function connection diagram through a residual image neural network model to obtain diagnostic information of neurodevelopmental disorder co-diseases; and the interpretable output module is used for outputting an abnormal brain region by taking the amplitude low-frequency fluctuation as a reference index.

The invention belongs to the technical field of nutritional compositions, and particularly relates to a composition, a preparation method thereof and application of the composition in protecting brain health. The composition provided by the invention is prepared from docosahexaenoic acid, 3-sialic acid lactose and phosphatidylserine. The composition is clear in sleep improvement effect, can effectively solve the problem of sleep maintenance caused by sleep deprivation, has the effects of protecting neural functions, improving memory and relieving anxiety from multiple dimensions, and can repair brain tissue damage and protect brain health. Based on the composition, products for assisting in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health and improving concentration can be developed, the health requirements of different people are comprehensively met, and the application value is high.

Provided are platforms, methods, and systems to customize virtual or augmented reality (collectively, XR) content for an individual or a group of individuals, such as to treat a user having a mental or neurodevelopmental disorder (e.g., autism), train or educate an individual (e.g., student) or a group of individuals, or otherwise attend to a special need of an individual or a group of individuals. A graphical user interface may be used to edit the XR content.

The present invention relates to a system for aiding the diagnosis of neurodevelopmental disorders and / or associated mental health disorders in a child or teenager user, the system comprising: an interface module configured to present an interactive program to the user, preferably the program being a game; the acquisition module is configured to receive a plurality of time biological characteristic signals generated by interaction of a user and the interface module at the same time when the user interacts with the program; an extraction module configured to extract or calculate, based on each temporal feature signal, at least one correlation feature for evaluating at least one symptom related to at least one neurodevelopmental disorder or associated mental health disorder of the child or teenager; and a classification module configured to assign one or more scores related to one or more symptoms to the user based on the features extracted or calculated by the extraction module and a machine learning model previously trained based on a set of annotation data collected from the child user, the one or more symptoms are associated with one or more neurodevelopmental disorders or associated mental health disorders.

The invention belongs to the technical field of food nutrition, and discloses application of an artemisia selengensis extract in preparation of a medicine for improving neurodevelopmental disorder and the medicine. The artemisia selengensis extract has the following advantages and effects: the research finds that the artemisia selengensis extract has the effect of improving neurodevelopmental disorders, which is specifically embodied in that the artemisia selengensis extract can effectively increase the activity of acetylcholin esterase, lower the content of ROS (reactive oxygen species), up-regulate antioxidant indexes (GSH (glutathione) content and sod1 and cat gene expression) and relieve oxidative stress injury of zebrafish caused by NP (natriuretic peptide); meanwhile, the artemisia selengensis extract can also up-regulate the expression of a neural development gene (alpha 1-tubulin, mbp) so as to improve the neural development disorder of the zebrafish; besides, the mechanism of improving the zebrafish neurodevelopmental disorder by the artemisia selengensis extract is mainly realized through a p38 / 5-HT / Wnt / beta-catenin signal channel, expression of p38a is down-regulated (network pharmacology finds that p38 in MAPHK is a main mechanism channel), and expression of htr1aa, maoa, wnt4a and beta-catenin is down-regulated.

The invention disclosed herein relates to metal-catalyst free, green enantioselective synthesis of sulfoxide compounds of Formula-I. Particularly, the present invention relates to in situ process to obtain enantioselective sulfoxide compounds of Formula-I with high yield and purity and specific optical rotation. Further, the enantioselective sulfoxide compounds of Formula-I are useful in the treatment of neurological, neuropsychiatric, metabolic and neurodevelopmental disorder.

The present invention relates to novel phosphate ester compounds of formula I for use in the treatment of central nervous system (CNS) diseases. Furthermore, the present invention provides an improved process for obtaining the compound of formula (I) in high yield and high purity. The novel phosphate ester compounds of formula-I are useful in the treatment of neurological, neuropsychiatric, metabolic and neurodevelopmental disorders.

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

This disclosure belongs to the field of medical testing technology, and specifically relates to a classification, diagnostic, and prediction method, system, and electronic device for congenital neurodevelopmental disorders. Addressing the clinical diagnostic challenges of congenital neurodevelopmental disorders, this disclosure establishes for the first time a classification, diagnostic, and prediction method for congenital neurodevelopmental disorders based on whole-genome methylation signatures and customized SVM machine learning. This method achieves one-stop differential diagnosis across multiple mechanisms and diseases, filling a gap in existing technologies and providing a novel and efficient solution for the accurate diagnosis of congenital neurodevelopmental disorders.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

The invention provides a network science-based method for evaluating a herbicide neurodevelopmental toxicity risk. The herbicide which is widely used and is detected at high frequency in the environment is collected; acquiring a herbicide target and risk genes of neurodevelopment disorder related diseases; constructing a herbicide target network and a disease module; analyzing the neuro-developmental toxicity risk of the herbicide by network proximity; constructing an overlapping network of a herbicide target network and a disease module; screening core pathogenic genes based on multiple network topology algorithms and carrying out gene enrichment analysis; the toxicity risk is evaluated from the molecular level, and the high-risk herbicide variety is effectively discriminated. And a neuro-developmental toxic molecular mechanism of the herbicide is analyzed based on a network analysis system, so that a new framework from risk assessment to mechanism analysis is constructed for toxicity research of environmental chemicals.

To provide an execution function evaluation device capable of evaluating an execution function related to a symptom of a neurodevelopmental disease group.SOLUTION: An execution function evaluation device 1 is an evaluation device for an execution function related to a symptom of a neurodevelopmental disease group, and includes: a memory 12 for storing operation information showing an operation by an evaluation object person A, the operation being for a virtual space in which a task is set, displayed in a user terminal 3; and an arithmetic part 11 for evaluating an execution function of the evaluation object person. An index of the execution function of the evaluation object person is calculated using relationships among a plurality of virtual spaces of the operation information by the evaluation object person in each of the plurality of virtual spaces with different set tasks, displayed in the user terminal.SELECTED DRAWING: Figure 1

Described herein are T-type voltage-gated calcium channel enhancers capable of enhancing thalamic function, e.g., reducing thalamic cortex hyperactivity in a patient in need thereof. These enhancers may be useful for many diseases or conditions associated therewith, such as schizophrenia and neurodevelopmental disorders. The CaV enhancers typically have a structure of formula (I) or formula (V). # imgabs0 #

The invention relates to the field of neurodevelopmental disorders, and discloses an electro-oculogram signal analysis and diagnosis system based on neurodevelopmental disorders, which extracts signal features from pre-processed electro-oculogram signals, and analyzes inter-group differences between signal features of a child patient group and signal features of a healthy child group. The method comprises the following steps: preliminarily screening out signal features with significant statistical difference between two groups, then carrying out severity correlation analysis on the screened signal features, screening and forming a feature list highly related to ADHD severity, and then comparing eye movement features of a child patient group under natural behaviors with eye movement features of a healthy child group, so as to obtain a feature list related to ADHD severity. The method comprises the following steps of: identifying and forming an abnormal signal feature list, fusing the feature list highly related to the ADHD severity and the abnormal signal feature list, calculating a comprehensive abnormal score, drawing an ROC curve according to the calculated comprehensive abnormal score, and carrying out grading evaluation on the ADHD severity of a child patient, so that accurate diagnosis and severity judgment on the ADHD disease are realized.

The disclosure provides a method of reducing occurrence of a neurodevelopmental disorder (ND) in a subject at risk for developing an ND, the method comprising administering a composition comprising an equol-producing bacterium or gut-health-promoting bacterium to the subject.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

The present invention relates to compounds of formula (Ia) and their pharmaceutical composition These compounds are for the use in the treatment of a disease or disorder selected from the group consisting of fungal infections, bacterial infections, neurological and neurodevelopmental disorders and cancer.

The invention discloses a method for constructing a neurodevelopmental disorder animal model based on central nervous system myelin sheath function change and application, and belongs to the technical field of biological engineering. An Msl2 gene conditional knockout mouse model is constructed by adopting a gene engineering technology, the space-time specific knockout of a second exon of the Msl2 gene in a specific cell type is realized through a Cre-LoxP recombinase system, and the exon encodes a key enzyme activity region for catalyzing ubiquitination. Model construction is based on central nervous system oligodendrocyte / myelin sheath dysfunction, the behavior phenotype of the model is similar to the behavior of a typical neurodevelopment disorder animal, a brand new perspective is provided for exploring an etiology mechanism, model mice can be prepared on a large scale by performing directional mating on the gene modified mice, and the development of the model is promoted. And consistency of different experiment batches and reliable reproduction of experiment data are ensured.

CASK-related disorders are caused by mutations in an important regulatory gene in the brain, calcium / calmodulin-dependent serine protein kinase (CASK) and can result in microcephaly with pontine and cerebellar hypoplasia (MICPCH), in addition to intellectual disability, and seizure activity. CASK-related Intellectual Disabilities (CASK-ID) predominantly affect the female population and are classified as X-linked neurodevelopmental disorders. CASK-ID is typically the result of a de novo loss of function mutation. As females have two Xchromosomes, disease causing mutations present with a 50 / 50 expression of mutant and wildtype, due to the mosaicism caused by random X-chromosome inactivation (XCI). This mosaicism presents an interesting therapeutic option of reactivating the intact allele in affected neurons. Disclosed herein are gene editing systems that can enhance in vivo CASK expression.

Methods of treating neurodevelopmental disorders by administering an acetylated amino acid having a carbon-nitrogen bond and acetyl group covalently bound to the nitrogen of the carbonnitrogen bond and having a three-dimensional structure that allows the acetylated amino acid to enter cells and neurons are described. In one embodiment, the acetylated amino acid is a compound of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 is each independently H or D, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the acetylated amino acid are also described.

Methods of treating a neurodevelopmental disorder caused by a mutation in HNRNPH2 or PCDH19, comprising downregulating expression of HNRNPH2 or PCDH19 in cells of the brain of a subject are provided. Antisense oligonucleotides useful in performing the methods of the invention are also provided.

Aspects of the present disclosure relate to expression cassettes encoding miniShank3 proteins, AAV vectors containing the expression cassettes, and gene therapy methods, particularly where the expression cassettes are formulated to further contain an AAV9 capsid, and the gene therapy is useful for treating neurodevelopmental disorders such as autism spectrum disorder (ASD) and Phelan-McDermid syndrome.

To provide a composition of trophinetide. [Solution] This disclosure describes a compound of formula (I), its stereoisomers, by-compounds, pharmaceutical compositions, and methods for producing such compounds using silylating agents, as well as methods for producing compositions and products produced using such methods. More specifically, this disclosure describes the production of trophinetides and by-products, compositions, and products containing such compounds for pharmaceutical applications for the treatment of neurodegenerative or neurodevelopmental disorders. JPEG2026063085000110.jpg55147

Described herein are antisense oligonucleotides (ASOs), vectors, and related compositions and methods for increasing endogenous expression of SHANK3 protein, and uses thereof in disorders associated with SHANK3 haploinsufficiency, such as Phelan-McDermid Syndrome.